In one reported case, a patient with advanced squamous cell lung cancer harboring an FGFR3-TACC3 fusion—identified via RNA sequencing and fusion transcript analysis—experienced sustained clinical benefit and disease control for 11 months while on erdafitinib therapy [237]. Here, FGFR3 is linked to squamous cell lung carcinoma.